Matched analysis from the IGOS dataset showed ANX005-treated patients had greater improvements in GBS disability scores over time compared with those receiving IVIg or plasma exchange.

AHN's neuro-oncology program aims to revolutionize brain and spine tumor care with innovative therapies, personalized treatment plans, and advanced research initiatives.

The assistant professor of neurology at Robert Wood Johnson Medical School discussed the mission of RCASIA, highlights from its annual retreat, and key takeaways from AAN 2025.

Subgroup data from a phase 2 CIDP trial showed riliprubart maintained consistent efficacy and safety across patient demographics, disease characteristics, and prior treatment exposures.

Findings suggest a potential correlation between motor function improvement and decreased autophagy-related protein levels in patients with spinal muscular atrophy treated with nusinersen.

A newly presented study showed that patients with sarcopenia before starting chemotherapy had a greater likelihood of developing moderate to severe peripheral neurotoxicity.

Eplontersen showed promise in halting disability progression and improving gait speed in patients with hereditary amyloid polyneuropathy, according to recent study findings.

A recently presented biobank data analysis showed associations between reduced transthyretin and higher incidence of conditions such as Alzheimer disease, cardiovascular disease, and rheumatoid arthritis.

Among patients with severe Guillain-Barré syndrome, imlifidase plus IVIg resulted in improved mobility, strength, and disability scores, with sustained benefit over a 6-month time period.

A recently presented matching-adjusted indirect comparison assessed outcomes of immune globulin subcutaneous (Human)-ifas, 10% solution versus subcutaneous efgartigimod in patients with CIDP.

Carba1 showed promise in preclinical models as a dual-action agent, protecting against chemotherapy-induced neuropathy while preserving anticancer efficacy and safety.

Here's some of what is coming soon to NeurologyLive® this week.

Presented at the 2025 PNS Annual Meeting, phase 2 ARDA data showed empasiprubart reduced IVIg retreatment risk and improved grip strength in patients with MMN.

New data from a phase 2 study presented at the 2025 PNS Annual Meeting showed that riliprubart reduced plasma NfL levels in CIDP, with greater reductions linked to stronger functional improvements.

Patients with Guillain-Barré syndrome treated with tanruprubart, formerly known as ANX005, reported significant benefits in mobility, self-care, and usual activity compared with placebo.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Peripheral Nerve Society Annual Meeting.

A groundbreaking CRISPR therapy shows promise in treating hereditary ATTR amyloidosis, achieving significant serum TTR reductions and stable patient outcomes.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 16, 2025.

The FDA approved Fujirebio's Lumipulse G p-tau217/β-Amyloid 1-42 Plasma Ratio as the first in vivo blood test for early Alzheimer’s detection, demonstrating high diagnostic accuracy with strong correlations to amyloid PET and CSF test results.

Markted as Brekiya, Amneal Pharmaceuticals’ newly approved therapy offers a self-administered version of dihydroergotamine mesylate for adults with migraine or cluster headache.

Targeting tau pathology in preclinical Alzheimer disease could benefit from recruiting individuals positive for both Aß and GFAP biomarkers, improving patient selection and cost effectiveness.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Ajay Gupta, MD. [LISTEN TIME: 17 minutes]

Verdiperstat showed no significant impact on ALS progression in a recent trial, highlighting the challenges of developing effective treatments for this disease.

Peter Gliebus, MD, discusses the clinical complexity of frontotemporal dementia and how Baptist Health’s symposium is helping to prepare the field for future advances in diagnosis and treatment.

Seif Elbualy, MD, discusses his role at the Brain and Spine Symposium and shares insights on the future of interventional pain management, evolving techniques, and pharmaceutical innovation.